Persephone Biosciences Inc. is a pioneer in synthetic biology, reimagining patient and infant health through the development of microbiome-based medicines. Persephone is building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems.
We are truly honored to have Propel Bio Partners as an investor. We believe that Propel Bio’s deep expertise and network in biotech, operations and financing will be invaluable to the success of our company as we scale. Propel Bio in just a short few weeks as proven to be a true partner in our mission and beyond capital, have provided critical resources to help us solve our immediate challenges in an efficient way.
Stephanie Culler, PhD
Inherent Biosciences, Inc. is a biotechnology company pioneering epigenetic medicine for complex diseases. The company’s epigenetic platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics, to radically transform how we diagnose and treat complex diseases like infertility.
We're thrilled to partner with you and your team at Propel Bio. Most exciting to us is the deep bench of technology, commercial and operating expertise Propel brings to Inherent. Equally exhilarating are the connections you and your team have to the critical growth capital needed in the coming years as our pioneering innovations become standard of care. It's reassuring to know we'll have the capital and your dream team to help propel our company to success and outsized returns.
Andy Olson, MBA
OmniVis has developed an integrated platform to transform the speed, accuracy, and economics of point-of-care pathogen detection. OmniVis’ ultrasensitive handheld device rapidly detect dangerous pathogens anywhere in the world – a lab in your palm.